PMID: 15334762Sep 1, 2004Paper

Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia

The Journal of Extra-corporeal Technology
Brian MejakLynn Boshkov

Abstract

We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/ kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery
Alan I SmithMikhail Vaynblat
ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs
Michael L SchmitzRobert D B Jaquiss
The Journal of Extra-corporeal Technology
N JohnstonLynne Huber
© 2021 Meta ULC. All rights reserved